Executive Director
Vaxcyte
Executive Director
Vaxcyte
Develops broad-spectrum vaccines for bacterial infections
The Executive Director, Digital Enablement (DE) is a newly created role with a mandate to ensure that digital and AI capabilities give Vaxcyte better leverage across every launch function. Initially focused on the commercial launch of VAX-31 for the adult indication, this role will lead the build of the digital infrastructure, AI capabilities, and commercial technology roadmap from the ground up for Vaxcyte as a first-time launching company.
The Executive Director, DE serves as an enabler across functions, designing systems and capabilities so that Marketing, Sales, Medical Affairs, Market Access, Commercial Operations (e.g. 3PL, Distribution, Customer Service, etc), Data and Analytics and any other commercial teams have less friction, better intelligence, and more leverage than the competition. The DE will work collaboratively with these partners to determine business needs and recommend/build system capabilities across the organization
This role sits within the Commercial organization and works in close partnership with the IT Commercial Lead (ITCL) in the IT function, who will own implementation, data security, and technical management. This role will own strategy through execution and ensure our launch functions are fully enabled.
This role also supports the digital, data, and AI needs of Medical Affairs as one of several functions it enables, while respecting the independence of Medical Affairs in setting its own scientific strategy, content, and engagement priorities. All Medical Affairs enablement operates within the company’s compliance framework, preserving the separation of promotional and non-promotional activity and the independence of scientific engagement.
Commercial Digital Strategy and Product Roadmap
Cross-Functional Leadership and Business Translation
AI-First Capability Building
Vendor and Platform Governance
Data Strategy and Commercial Performance Reporting
BA/BS degree in a scientific discipline, business, marketing, or technology required. MBA or other advanced degree highly desired. Minimum of 16+ years of industry-related experience with 5+ years in commercial or commercial-facing roles within pharmaceutical, biotech, or vaccine organizations, including direct exposure to product launch. Other combinations of education and/or experience may be considered.
Equal Opportunity
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
Recruitment Fraud Notice
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at vaxcyte.com/careers.
Vaxcyte develops vaccines to prevent bacterial infections, focusing on broad-spectrum pneumococcal vaccines and other targets like Group A Strep, periodontitis, and Shigella. Its lead product, VAX-24, covers 24 Streptococcus pneumoniae strains and is produced using the XpressCF cell-free protein synthesis platform, which enables multi-strain conjugate vaccines. The company differentiates itself by combining cell-free manufacturing with broad strain coverage and has FDA Breakthrough Therapy designation for VAX-24, helping speed development. Its goal is to bring broadly protective bacterial vaccines to market, reduce serious infections worldwide, and expand its portfolio with products like VAX-31 and additional preclinical candidates.
Explore more opportunities at Vaxcyte